CN1956963A - 制备n-哌啶子基-1,5-二苯基吡唑-3-羧酰胺衍生物的方法 - Google Patents
制备n-哌啶子基-1,5-二苯基吡唑-3-羧酰胺衍生物的方法 Download PDFInfo
- Publication number
- CN1956963A CN1956963A CNA2005800163474A CN200580016347A CN1956963A CN 1956963 A CN1956963 A CN 1956963A CN A2005800163474 A CNA2005800163474 A CN A2005800163474A CN 200580016347 A CN200580016347 A CN 200580016347A CN 1956963 A CN1956963 A CN 1956963A
- Authority
- CN
- China
- Prior art keywords
- sub
- formula
- compound
- phenyl
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明涉及制备式(I)化合物及其盐的方法,其中R1代表氢或卤素原子(C1-C4)烷基;R2,R3,R4,R5,R6和R7彼此独立地代表氢或卤素原子或(C1-C4)烷基,(C1-C4)烷氧基或三氟甲基。
Description
本发明的主题涉及制备下式化合物的方法:
其中:
-R1代表氢原子或卤素原子或(C1-C4)烷基;
-R2,R3,R4,R5,R6和R7代表,彼此独立地,氢原子或卤素原子或(C1-C4)烷基,(C1-C4)烷氧基或三氟甲基;及其盐。
多个专利或专利申请EP 0 656 354 B,EP 1 150 961 B中均揭露了式(I)化合物,其作为***类物质(cannabinoid)CB1受体拮抗体。更特别地,N-哌啶子基-5-(4-氯-苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-羧酰胺或利莫那班(rimonabant)对于肥胖和戒烟具有临床活性。
现有技术中已知使用N-氨基哌啶对酸功能衍生物作用制备式(I)化合物:
尤其在专利EP 0 656 354 B中描述了制备利莫那班合成方法。例如使用烷基酯或酰基氯作为功能衍生物。
根据本发明,式(I)化合物通过下述方法制备得到,其特征在于让式X-(CH2)5-X’(II)戊烷衍生物(其中X和X’各自独立地代表卤素原子或YSO2O-基团,其中Y代表(C1-C4)烷基,(C1-C4)全氟烷基,未取代苯基或被甲基、氯或硝基取代的苯基)与下式吡唑-3-碳酰肼衍生物反应:
其中R1,R2,R3,R4,R5,R6和R7如(I)中所定义。
在室温与溶剂回流温度之间的温度下,在溶剂中并存在碱的情况下实施该反应。
根据本发明,在该方法中特别使用式(II)化合物,其中X和X’各自独立地代表卤素原子。
还特别使用式(II)化合物,其中X和X’各自独立地代表YSO2O-基团,其中Y如上述所定义。
根据本发明的一个优选实施方式,其特征在于由式(II)化合物与下式5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-碳酰肼作用制备利莫那班:
根据本发明的一个优选实施方式,将式(II)1,5-二卤代戊烷与5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-碳酰肼(IIIa)反应。
更特别地,1,5-二溴戊烷与5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-碳酰肼(IIIa)反应。
在有机碱或无机碱的存在下实施该反应,该有机碱如叔胺,例如三乙胺,该无机碱如NaOH,KOH,K2CO3,Na2CO3或Cs2CO3。
在芳族溶剂、醚溶剂、二烷或腈溶剂中实施该反应,该芳族溶剂例如甲苯或氯苯,该醚溶剂如四氢呋喃、二甲氧基乙烷,该腈溶剂例如乙腈或丙腈。
优选地,在三乙胺或Na2CO3或K2CO3的存在下在乙腈中实施该反应。
非常特别优选,在Na2CO3存在下加热回流乙腈中实施该反应。
特别地,本发明的主题是制备N-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-羧酰胺及其盐的方法,其特征在于在Na2CO3存在下加热回流乙腈中将1,5-二溴戊烷与式(IIIa)化合物反应。
术语“卤素原子”是指溴、氯或碘。
式(III)化合物和其制备方法是现有技术已知的:Canadian J.Chem.,1963,41(7),1813-1818;J.Chem.Engineering Data,1977,22(1),104-110;J.Med.Chem.,2002,45,2708-2719。
文献J.Med.Chem.,2002特别描述了5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-碳酰肼及由其相应的酰基氯的制备。
下述实施例用于说明本发明,但是不作为对本发明的限定。
在实施例中和在说明书中使用了下式简写:
DCM:二氯甲烷。
该质谱以所谓电喷射(ES)离子化模式测量。
该核磁共振(1H NMR)谱是在d6-DMSO或CDCl3中,在200MHz或300MHz下得到。该化学位移值δ以ppm份表示。
在NMR中所观察到的信号表示如下:s:单峰;bs:宽单峰;d:双重峰;sd:***双重峰;t:三重峰;st:***三重峰;q:四重峰;bup:未分开宽峰;mt:多重峰。
制备1:
5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-碳酰肼
在氮气下,在100ml乙醇中放入20g 5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-碳酰氯,将该混合物加热回流2小时。使其回到20-25℃,然后加入50g水合肼,将该混合物再次加热回流3.5小时。趁热过滤该反应介质,然后蒸干乙醇。浓缩该反应介质,然后取入150mlDCM中并沉降分离。抛去水相,使用100ml水洗涤该有机相两次,然后蒸发DCM。真空干燥后,得到16.9g所需化合物。
ES+:[M+Na]+=417,419,421,423
ES-:[M-H]-=393,395,397,399
NMR(CDCl3,1H,300MHz):2.35ppm:s:3H;4.0ppm:d:2H;7.04ppm:m:2H;7.25ppm:bm:4H;7.41ppm:d:1H;8.04ppm:m:1H。
实施例1
N-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-羧酰胺
在氮气下,将10g在制备1中得到的化合物与5.3g碳酸钠放入100ml乙腈中。加热该反应介质至乙腈回流,加入总量6.9ml 1,5-二溴戊烷,然后持续加热回流45小时。加入50ml水水解该介质,沉降分离,抛去水相。使用50m饱和NaCl水溶液洗涤该有机相两次。蒸发干燥乙腈,得到18.4g粗产品。将得到的粗产品经过硅胶色谱分离(洗提液:环己烷/丙酮:75/25;v/v)。将得到的产物取入100ml甲基环已烷并重结晶。得到5.7g纯的所需产品。
NMR(d6-DMSO,1H,200MHz):1.31ppm:bm:2H;1.55ppm:bm:4H;2.22ppm:s:3H;4.0ppm:d:2H;7.22ppm:d:2H;7.43ppm:d:2H;7.56ppm:sd:1H;7.71ppm:d:1H;7.76ppm:d:1H;9.02ppm:s:1H。
Claims (11)
2.如权利要求1所述方法,其特征在于在式(II)中X和X’各自独立地代表卤素原子。
3.如权利要求1所述方法,其特征在于在式(II)化合物中X和X’各自独立地代表Y-SO2-O-基团,其中Y如权利要求1所定义。
5.如权利要求4所述方法,其特征在于1,5-二卤代戊烷与式(IIIa)化合物反应。
6.如权利要求5所述方法,其特征在于1,5-二溴戊烷与式(IIIa)化合物反应。
7.如权利要求1-6中任一项所述方法,其特征在于该碱选自三乙胺、NaOH、KOH、K2CO3、Na2CO3或Cs2CO3。
8.如权利要求1-7中任一项所述方法,其特征在于该溶剂选自甲苯、氯苯、四氢呋喃、二甲氧基乙烷、二烷、乙腈或丙腈。
9.如权利要求1-8中任一项所述方法,其特征在于在三乙胺、Na2CO3或K2CO3存在下,在乙腈中实施该反应。
10.如权利要求1-9中任一项所述方法,其特征在于在Na2CO3存在下,在加热回流乙腈中实施该反应。
11.一种制备N-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-吡唑-3-羧酰胺及其盐的方法,其特征在于在Na2CO3存在下,在加热回流乙腈中将1,5-二溴戊烷与下式化合物反应:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0408111A FR2873372B1 (fr) | 2004-07-22 | 2004-07-22 | Procede de preparation de derives n-piperidino-1,5- diphenylpyrazole-3-carboxamide |
FR0408111 | 2004-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1956963A true CN1956963A (zh) | 2007-05-02 |
CN100537543C CN100537543C (zh) | 2009-09-09 |
Family
ID=34949586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005800163474A Expired - Fee Related CN100537543C (zh) | 2004-07-22 | 2005-07-20 | 制备n-哌啶子基-1,5-二苯基吡唑-3-羧酰胺衍生物的方法 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7462632B2 (zh) |
EP (1) | EP1773783B1 (zh) |
JP (1) | JP4879175B2 (zh) |
KR (1) | KR20070036050A (zh) |
CN (1) | CN100537543C (zh) |
AR (1) | AR049995A1 (zh) |
AT (1) | ATE466843T1 (zh) |
AU (1) | AU2005276350A1 (zh) |
BR (1) | BRPI0510399A (zh) |
CA (1) | CA2564223A1 (zh) |
DE (1) | DE602005021110D1 (zh) |
FR (1) | FR2873372B1 (zh) |
IL (1) | IL179107A0 (zh) |
MA (1) | MA28576B1 (zh) |
MX (1) | MXPA06012954A (zh) |
NO (1) | NO20071008L (zh) |
RU (1) | RU2329252C1 (zh) |
TW (1) | TW200609223A (zh) |
UY (1) | UY29023A1 (zh) |
WO (1) | WO2006021652A1 (zh) |
ZA (1) | ZA200609639B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1816125A1 (en) * | 2006-02-02 | 2007-08-08 | Ranbaxy Laboratories, Ltd. | Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof |
US20100076022A1 (en) * | 2006-09-01 | 2010-03-25 | Hetero Drugs Limited | Novel polymorphs of rimonabant |
WO2008032330A2 (en) * | 2006-09-11 | 2008-03-20 | Hetero Drugs Limited | Improved process for rimonabant |
WO2008035023A1 (en) * | 2006-09-19 | 2008-03-27 | Cipla Limited | Polymorphs of rimonabant |
EP1944297A1 (en) * | 2007-01-09 | 2008-07-16 | Miklós Vértessy | Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof |
EP1947090A1 (en) * | 2007-01-17 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Method for preparing N-piperidino-1,5-diphenylpyrazole-3-carboxamide and derivatives |
WO2008088900A2 (en) * | 2007-01-18 | 2008-07-24 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of rimonabant base and processes for preparation thereof |
US8431609B2 (en) | 2007-02-19 | 2013-04-30 | Darmesh Mahendrabhai Shah | Process for preparation of pyrazole derivatives |
FR2913018A1 (fr) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs |
WO2009109222A1 (en) * | 2008-03-04 | 2009-09-11 | Maprimed, S. A. | Process for the preparation of rimonabant |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
JP4314339B2 (ja) * | 2002-08-22 | 2009-08-12 | 三井化学アグロ株式会社 | ニコチンアミドラゾン誘導体 |
-
2004
- 2004-07-22 FR FR0408111A patent/FR2873372B1/fr not_active Expired - Fee Related
-
2005
- 2005-07-19 UY UY29023A patent/UY29023A1/es not_active Application Discontinuation
- 2005-07-19 AR ARP050102971A patent/AR049995A1/es unknown
- 2005-07-20 CN CNB2005800163474A patent/CN100537543C/zh not_active Expired - Fee Related
- 2005-07-20 KR KR1020067024365A patent/KR20070036050A/ko not_active Application Discontinuation
- 2005-07-20 MX MXPA06012954A patent/MXPA06012954A/es not_active Application Discontinuation
- 2005-07-20 CA CA002564223A patent/CA2564223A1/fr not_active Abandoned
- 2005-07-20 DE DE602005021110T patent/DE602005021110D1/de active Active
- 2005-07-20 WO PCT/FR2005/001850 patent/WO2006021652A1/fr active Application Filing
- 2005-07-20 EP EP05790868A patent/EP1773783B1/fr active Active
- 2005-07-20 JP JP2007521985A patent/JP4879175B2/ja not_active Expired - Fee Related
- 2005-07-20 AU AU2005276350A patent/AU2005276350A1/en not_active Abandoned
- 2005-07-20 ZA ZA200609639A patent/ZA200609639B/xx unknown
- 2005-07-20 BR BRPI0510399-1A patent/BRPI0510399A/pt not_active IP Right Cessation
- 2005-07-20 RU RU2006141239/04A patent/RU2329252C1/ru not_active IP Right Cessation
- 2005-07-20 AT AT05790868T patent/ATE466843T1/de not_active IP Right Cessation
- 2005-07-21 TW TW094124731A patent/TW200609223A/zh unknown
-
2006
- 2006-11-07 IL IL179107A patent/IL179107A0/en unknown
- 2006-11-10 MA MA29444A patent/MA28576B1/fr unknown
- 2006-11-14 US US11/559,566 patent/US7462632B2/en not_active Expired - Fee Related
-
2007
- 2007-02-21 NO NO20071008A patent/NO20071008L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2008506756A (ja) | 2008-03-06 |
RU2329252C1 (ru) | 2008-07-20 |
ZA200609639B (en) | 2008-08-27 |
FR2873372B1 (fr) | 2006-09-08 |
TW200609223A (en) | 2006-03-16 |
ATE466843T1 (de) | 2010-05-15 |
DE602005021110D1 (de) | 2010-06-17 |
WO2006021652A1 (fr) | 2006-03-02 |
FR2873372A1 (fr) | 2006-01-27 |
AU2005276350A1 (en) | 2006-03-02 |
JP4879175B2 (ja) | 2012-02-22 |
US20080119653A1 (en) | 2008-05-22 |
CN100537543C (zh) | 2009-09-09 |
IL179107A0 (en) | 2007-03-08 |
KR20070036050A (ko) | 2007-04-02 |
MA28576B1 (fr) | 2007-05-02 |
UY29023A1 (es) | 2006-02-24 |
NO20071008L (no) | 2007-02-21 |
US7462632B2 (en) | 2008-12-09 |
BRPI0510399A (pt) | 2007-11-13 |
EP1773783A1 (fr) | 2007-04-18 |
CA2564223A1 (fr) | 2006-03-02 |
MXPA06012954A (es) | 2007-02-12 |
EP1773783B1 (fr) | 2010-05-05 |
AR049995A1 (es) | 2006-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1956963A (zh) | 制备n-哌啶子基-1,5-二苯基吡唑-3-羧酰胺衍生物的方法 | |
JP6367556B2 (ja) | ピラゾール−4−カルボキサミドの製造方法 | |
BR112019019605B1 (pt) | Compostos e processo para preparar um composto de fórmula ii-a | |
JP6078563B2 (ja) | フェニルが置換された3−ジフルオロメチル−1−メチル−1h−ピラゾール−4−カルボン酸n−メトキシ−[1−メチル−2−フェニルエチル]アミドを調製するためのプロセス | |
SK278578B6 (en) | Preparation method of benzcycloalkenyldihydroxyalkanoic acids derivatives | |
Rahmani et al. | Propylphosphonium hydrogen carbonate ionic liquid supported on nano-silica as a reusable catalyst for the efficient multicomponent synthesis of fully substituted pyridines and bis-pyridines | |
CN102659683B (zh) | 5-烷氧基-4-羟基甲基吡唑化合物的制备方法 | |
CN110511189B (zh) | 5-氨基-1,2,4-噁二唑类衍生物及其合成方法 | |
JPWO2012169468A1 (ja) | シクロペンタノン化合物の製造方法、および中間体化合物 | |
KR20090061030A (ko) | 페닐옥시아닐린 유도체 | |
EP2669268B1 (en) | Process for production of aromatic amide carboxylic acid derivative | |
JP4855392B2 (ja) | 1,5−ジフェニルピラゾールカルボン酸誘導体の調製方法 | |
JP5036198B2 (ja) | フルオレン骨格含有フタルイミド類及びそれから誘導されるジアミン類 | |
JP4975738B2 (ja) | 2−アルケニル−3−アミノチオフェン誘導体及びその製造方法 | |
JP4061333B2 (ja) | 2−(ピラゾール−1−イル)ピリジン誘導体 | |
EP1824806A1 (en) | Chemical compounds | |
JP2009057359A (ja) | アミンボランを用いる含フッ素アミン化合物の製造方法 | |
JP2009091267A (ja) | アミド誘導体及びそれらを有効成分とするスフィンゴシン−1−リン酸−1(s1p1)受容体選択的アゴニスト | |
KR100760015B1 (ko) | 벤조피란 화합물 합성용 중간체 | |
CN115246781A (zh) | 一种沙芬酰胺的制备方法 | |
CN103038208B (zh) | 制备西格玛受体抑制剂合成用1-芳基-吡唑-3-酮中间体的方法 | |
KR100740325B1 (ko) | 치환된 벤조피란 화합물 합성용 화합물 | |
JPH07252234A (ja) | 2−シアノイミダゾール系化合物の製造方法 | |
JP2003146974A (ja) | 4,5−ジ置換−1,2,3−トリアゾール及びその製造法 | |
JP2005047853A (ja) | 含窒素ヘテロ環化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1106228 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090909 Termination date: 20100720 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1106228 Country of ref document: HK |